BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17331468)

  • 1. A novel structure-based virtual screening model for the hERG channel blockers.
    Du L; Li M; You Q; Xia L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
    Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
    J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
    Zachariae U; Giordanetto F; Leach AG
    J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies.
    Farid R; Day T; Friesner RA; Pearlstein RA
    Bioorg Med Chem; 2006 May; 14(9):3160-73. PubMed ID: 16413785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward a consensus model of the HERG potassium channel.
    Stary A; Wacker SJ; Boukharta L; Zachariae U; Karimi-Nejad Y; Aqvist J; Vriend G; de Groot BL
    ChemMedChem; 2010 Mar; 5(3):455-67. PubMed ID: 20104563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computer simulations of structure-activity relationships for HERG channel blockers.
    Boukharta L; Keränen H; Stary-Weinzinger A; Wallin G; de Groot BL; Aqvist J
    Biochemistry; 2011 Jul; 50(27):6146-56. PubMed ID: 21657256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM; Ecker GF
    Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY; Yang SJ
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.
    Leong MK
    Chem Res Toxicol; 2007 Feb; 20(2):217-26. PubMed ID: 17261034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
    Doddareddy MR; Klaasse EC; Shagufta ; Ijzerman AP; Bender A
    ChemMedChem; 2010 May; 5(5):716-29. PubMed ID: 20349498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
    Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
    Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A composite model for HERG blockade.
    Kramer C; Beck B; Kriegl JM; Clark T
    ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuning out of hERG.
    Aronov AM
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):128-40. PubMed ID: 18175275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive in silico modeling for hERG channel blockers.
    Aronov AM
    Drug Discov Today; 2005 Jan; 10(2):149-55. PubMed ID: 15718164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hERG classification model based on a combination of support vector machine method and GRIND descriptors.
    Li Q; Jørgensen FS; Oprea T; Brunak S; Taboureau O
    Mol Pharm; 2008; 5(1):117-27. PubMed ID: 18197627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.
    Ekins S; Balakin KV; Savchuk N; Ivanenkov Y
    J Med Chem; 2006 Aug; 49(17):5059-71. PubMed ID: 16913696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of hERG channel blockers using a decision tree.
    Gepp MM; Hutter MC
    Bioorg Med Chem; 2006 Aug; 14(15):5325-32. PubMed ID: 16616507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies.
    Masetti M; Cavalli A; Recanatini M
    J Comput Chem; 2008 Apr; 29(5):795-808. PubMed ID: 17926340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular dynamics and continuum electrostatics studies of inactivation in the HERG potassium channel.
    Kutteh R; Vandenberg JI; Kuyucak S
    J Phys Chem B; 2007 Feb; 111(5):1090-8. PubMed ID: 17266262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.